FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 399 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Lung Cancer Trial of Osimertinib Draws Praise—and Some Criticism July 5, 2023 New reports show staff shortages continue to hold back cancer care June 9, 2022 First-Line 177Lu-Dotatate Plus Octreotide LAR Significantly Extends PFS in Patients with... June 13, 2024 Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 Load more HOT NEWS Italian Association of Oncology Nurses Maps the Situation of Cancer Patients... Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... Adjusting to the Challenges of Life After Cancer: An Expert Perspective EMA Recommends Granting a Marketing Authorisation for Asciminib
